Anti-obesity treatment could cost as little as $3 per month: StudyAnti-obesity treatment could cost as little as $3 per month: Study
A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to boost health in low- and middle-income countries.
MRI supplemental to digital breast tomosynthesis averts additional breast cancer deathsMRI supplemental to digital breast tomosynthesis averts additional breast cancer deaths
For women aged 40 years and older with extremely dense breasts, digital breast tomosynthesis (DBT) with supplemental magnetic resonance imaging (MRI) averts additional breast cancer deaths and results in more false-positive biopsy recommendations, according to a study published online March 2 in Annals of Internal Medicine.
‘Game-changing’ urine tests could detect breast cancer, endometriosis and PCOS’Game-changing’ urine tests could detect breast cancer, endometriosis and PCOS
New tests are being developed to spot early signs of breast cancer and endometriosis in urine.
GLP-1 drugs like Ozempic can curb addiction risk, study findsGLP-1 drugs like Ozempic can curb addiction risk, study finds
A large study of data from Veterans Affairs finds that people on GLP-1 drugs were less likely to develop substance abuse disorder or overdose. A large study of data from Veterans Affairs finds that people on GLP-1 drugs were less likely to develop substance abuse disorder or overdose.
Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesityTrial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity
A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue. In the paper “Bimagrumab and semaglutide alone or in combination for the treatment of obesity: Read More
STAT+: Omada reports first profitable quarter as it seizes broad GLP-1 opportunitySTAT+: Omada reports first profitable quarter as it seizes broad GLP-1 opportunity
Digital chronic care company Omada reported a quarterly profit for the first time since going public less than a year ago, the company revealed while announcing its full year 2025 earnings Thursday. Omada also provided earnings guidance for 2026, suggesting the company will continue to grow as it capitalizes on the demand for popular GLP-1 Read More
GLP-1 Drugs May Prevent, Treat Multiple AddictionsGLP-1 Drugs May Prevent, Treat Multiple Addictions
(MedPage Today) — Initiation of a GLP-1 receptor agonist was tied to lower risks of several substance use disorders (SUDs) in adults with type 2 diabetes, according to a target trial emulation using data on veterans. In patients without a history… (MedPage Today) — Initiation of a GLP-1 receptor agonist was tied to lower Read More
Ozempic-style drugs could slash complication risks after heart attacks, research suggestsOzempic-style drugs could slash complication risks after heart attacks, research suggests
A popular class of weight-loss drugs may prevent life-threatening cardiac complications by opening microscopic blood vessels that often remain blocked after a heart attack, according to a study published this week in Nature Communications. The research, led by the University of Bristol and University College London, identified a biological brain-gut-heart signaling pathway. This discovery appears Read More
GLP‑1 drugs like Ozempic may lower the risk of addiction: New studyGLP‑1 drugs like Ozempic may lower the risk of addiction: New study
A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction—and help people who already have one, a new study shows. A class of medications best known for treating diabetes and obesity may also reduce the risk of addiction—and help people who already have one, a new study Read More
What to know about how GLP-1 medications might fight addictionWhat to know about how GLP-1 medications might fight addiction
The blockbuster GLP-1 drugs that have reshaped the treatment of diabetes and obesity may help prevent multiple substance use disorders—and reduce the tragic outcomes they cause, a large new study finds. The blockbuster GLP-1 drugs that have reshaped the treatment of diabetes and obesity may help prevent multiple substance use disorders—and reduce the tragic outcomes Read More